Lineage Posts Series of Webinars Highlighting Recent Progress With its Three Clinical-Stage Allogeneic Cell Transplant Progra...
January 21 2021 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing allogeneic cell
therapies to address unmet medical needs, recently highlighted to
members of the investment community its clinical and operational
progress through a series of webinars hosted by FORCE Wealth with
presentations by Brian M. Culley, Chief Executive Officer. The
seminars covered all three of the company’s clinical-stage product
development programs: OpRegen®, a retinal pigment epithelium (RPE)
cell transplant for the treatment of dry age-related macular
degeneration (AMD), OPC1, an oligodendrocyte progenitor cell
transplant for the treatment of acute spinal cord injuries, and
VAC2, a dendritic cell transplant for the treatment of cancer.
Interested investors can now access all three presentations on the
Media section of Lineage’s website.
Lineage Cell Therapeutics: The Eyes of the World A
fireside chat hosted by Robert Rothman, M.D., Clinical Assistant
Professor, Ophthalmology at the Zucker School of Medicine at
Hofstra/Norwell and Principal, InFocus Capital Partners, an
ophthalmology-focused venture capital firm, on January 14, 2021,
discussing Lineage’s OpRegen program and the dry AMD therapeutic
landscape and commercial opportunity.
Lineage Cell Therapeutics: A Fireside Chat on Regenerative
Medicine A fireside chat hosted by Joseph Pantginis, Ph.D.,
Director of Research and Managing Director, Equity Research at H.C.
Wainwright & Co. Inc., on December 8, 2020, discussing
Lineage’s pipeline and the regenerative medicine landscape.
Lineage Cell Therapeutics: From Paralysis to Pitching –
Improving Mobility After a Severe Spinal Cord Injury A
presentation and Q&A session on October 22, 2020, discussing
Lineage’s OPC1 program and the spinal cord injury disease
landscape, treatment approaches, and the commercial opportunity of
restoring mobility to individuals who have been paralyzed by a
cervical spinal cord injury.
“Lineage and some more recently established competitors in the
field of allogeneic cell therapy are helping to demonstrate the
viability and commercial potential of using allogeneic cell
transplants to treat or cure serious diseases or conditions that
represent major unmet medical needs and large market
opportunities,” stated Brian M. Culley, Lineage CEO. “As the tools
and methods used to manufacture and test these therapies in
patients are reaching maturity, public policy and investor support
for cell therapy has moved in a positive direction. As we prepare
to advance our product candidates into later-stage clinical trials,
we are working to position Lineage to benefit from this convergence
of positive factors and help to accelerate the development and
commercialization of this novel branch of medicine.”
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210121005232/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024